Halozyme Therapeutics Inc (HALO)

[XenaLives]

Link doesn't seem to work so here are links to presentation abstracts:

Abstract Number: 39
Presentation Title: UDP-N-acetylglucosamine as a regulator of cancer cell signaling and microenvironment
Presentation Time: Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=eb59f5a2-3d2a-4ee5-9ed0-5c468da0a3a8&cKey=0a5a52c8-5cd8-44b5-aedb-85374b02a61e&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267


Abstract Number: 1217
Presentation Title: Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors
Presentation Time: Monday, Apr 18, 2016, 8:00 AM -12:00 PM

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=bb5dcf16-e379-432f-a72c-191183729d7b&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267


Abstract Number: 4886
Presentation Title: PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer
Presentation Time: Wednesday, Apr 20, 2016, 7:30 AM -11:00 AM

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=7e29eea8-2919-415b-8225-9605d44075b1&cKey=fd03fab2-169d-48f5-a484-8e4def634287&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267


Abstract Number: 283
Presentation Title: PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances pemetrexed antitumor efficacy in a human nonsquamous NSCLC xenograft model
Presentation Time: Sunday, Apr 17, 2016, 1:00 PM - 5:00 PM

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8f12fb61-c4bc-4343-8b71-06552cd95a69&cKey=51f803a0-0b10-492d-9163-b3d7c0b42fef&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267


Abstract Number: 2463
Presentation Title: PEGPH20 increases the anticancer activity of standard chemotherapy combinations, vincristine (VIN) and D actinomycin (DACT), in a Wilms’ xenograft model
Presentation Time: Monday, Apr 18, 2016, 1:00 PM - 5:00 PM


http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=48925246-b6f3-45e7-a603-b6cdb4e0287d&cKey=11e33203-49a2-4419-95c5-6baa624f1c56&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267


Abstract Number: CT097
Presentation Title: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
Presentation Time: Tuesday, Apr 19, 2016, 10:58 AM -11:16 AM
Location: Room 391, Morial Convention Center
Webcast Status: Webcast Available
(notation here that slides are being witheld)

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b01a929a-449c-4fd7-89e5-7dc10238925f&cKey=39e0a216-850a-43fc-ab54-0727214f8117&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267